Urgent Spurious & Falsified Drug Alert: Suspension Carefen 90 ml (Ibuprofen) B# CN-035
Latest developments, a significant alert of an important medication has been formally announced by the Government Analyst, DTL Rawalpindi (WHO Prequalified) vide test report no. TRA-01-75009954 dated 24-12-2024 has declared the Suspension Carefen 90 ml (Ibuprofen) B# CN-035 by WellCare Pharma Sargodha Pakistan as of Spurious quality and Falsified. This post aims to furnish general public with critical information regarding this alert, including its consequences for both patients and healthcare professionals, as well as the necessary actions that one should take if anyone finds himself affected by this situation. It is imperative to stay informed in order to safeguard health and overall well-being of society at large.
This Alert has been initiated due to absence of active drug namely, Ibuprofen against the labelled claim. Further the Government Analyst in its report mentioned that the said product contained Paracetamol instead of Ibuprofen. This product was manufactured and distributed by M/s Wellcare Pharmaceuticals Sargodha Pakistan in retail sector. The Risk factor associated with use of this spurious medicine is that as it is commonly used to reduce inflammation and pain in conditions such as fever, arthritis etc. But the identified quality issue with this spurious and misbranded medicine may result in zero or reduced Efficacy, depending on the degree of exposure of medicine and the patient’s condition. Vulnerable populations, including elderly patients and those with existing gastrointestinal, hepatic conditions, may be at a higher risk with use of.
Action initiated: – In the Instant case the manufacturer has been directed to immediately alert the defected batch(s) of mentioned products from the market. All pharmacists and chemist working at distributions and pharmacies are also advised to immediately check their stocks and stop supplying this batch of product. Besides, authorities also directed the retailers/pharmacies/distributors to identify customers, and notify them at once, about the product alert of this product. Intimation to your customers may be enhanced by including a copy of alert notification through email/sms/copy or any other means.
The officials, further directed the corner concerned, that the remaining stock should be quarantined and returned to the supplier/ company under intimation to regulatory authorities. Moreover, Regulatory field force of DRAP and Provincial Regulatory authorities/Departments have also been informed regarding the subject matter of Suspension Carefen 90 ml (Ibuprofen) B# CN-035 by WellCare Pharma Sargodha Pakistan Alert. Likewise, it also has been directed to field force to increase vigilance within the supply chains of institutions/pharmacies/healthcare facilities that are likely to be affected by this affected batch of product. Supplementary to this, an advice for consumers / general public was also been issued stating therein, consumers should stop using this product bearing the Suspension Carefen 90 ml (Ibuprofen) B# CN-035 manufactured by WellCare Pharma Sargodha Pakistan
Conclusion
The recent alert concerning spurious drug associated with Suspension Carefen 90 ml (Ibuprofen) B# CN-035 emphasizes the importance of vigilance in managing medications, both among healthcare professionals who prescribe them and patients who utilize them! Always prioritize staying informed about potential dangers linked with prescribed medications; possessing such knowledge can indeed be life-saving.